🍄 10M American Microdosers in 2025

👋 Welcome

Hey friends,

This week feels like another reminder that the psychedelic conversation is no longer fringe. It’s layered, complicated, and happening in full view.

Federal officials are openly discussing therapeutic potential. Researchers are asking foundational evolutionary questions. Athletes are testing physical limits with altered states. Meanwhile, lawmakers warn how fragile progress still is, and entire programs struggle under the weight of regulation and execution.

Momentum is real. So are the growing pains.

Let’s get into it.

🔝 Weekly Highlights

• 🧠 Top federal drug officials acknowledge therapeutic promise—and criticize research barriers
  Senior federal officials are now publicly recognizing the therapeutic potential of psychedelics while calling out Schedule I restrictions as a major obstacle to research. The tone matters here. This is the language of systems beginning to soften, even if policy lags behind. Read more
  

• 🍄 Why did mushrooms evolve to produce psilocybin in the first place?
  A new preprint digs into one of the most fascinating questions in psychedelic science: not how psilocybin affects humans, but why fungi evolved to make it at all. Defense? Communication? Ecological advantage? Read the paper
  

• 🏃 Can LSD make you a better athlete? One man is running 500 miles to explore it
  An ultra-endurance runner pushes physical and psychological limits while openly experimenting with altered states—part curiosity, part endurance experiment. Read more

• 🎧 Curious how MDMA-assisted therapy actually works?
  We shared a full visual breakdown on Instagram explaining how MDMA-assisted therapy sessions are structured—from preparation to integration. View the breakdown

🧬 Quick Hits

RESEARCH 🔬

• ⏱️ Psilocybin changes how people experience time
  A new study explores altered time perception—timelessness, loops, and expanded duration—during psilocybin experiences. Read the study
  

• 🎨 Microdosing improves the quality of creative ideas—but not the quantity
  Findings suggest microdoses sharpen evaluation and refinement of ideas rather than increasing output volume. Read more
  

• 💙 MDMA-assisted therapy shows promise for long-term depression relief
  New evidence points toward durable improvements in depressive symptoms following MDMA-assisted therapy. Read more

POLICY 🏛️

• ⚠️ Lawmakers warn one mistake could derail psychedelic access efforts
  Bipartisan voices emphasize how fragile current momentum remains—and how missteps could slow progress nationwide. Read more
  

• 🌱 New Jersey approves a pilot psilocybin therapy program
  The state joins a growing list exploring structured therapeutic access. Read more
  

• 🏛️ Ohio lawmakers consider psychedelics for PTSD treatment
  Legislators explore potential applications for veterans and trauma-related care. Read more

BUSINESS 💼

• 📉 How Oregon’s magic mushroom experiment lost its way
  A critical examination of accessibility, cost barriers, and regulatory drift. Read more
  

• 📣 Definium launches an LSD mental health awareness campaign
  Corporate messaging begins defining LSD’s therapeutic narrative. Read more

CULTURE 🎭

• ⛪ Inside the world’s largest psychedelic mushroom church
  A deep look at belief, legality, and modern entheogenic religion. Read more
  

• 🧪 Inside Calgary’s massive psychedelic drug lab
  A rare glimpse into one of Canada’s largest psychedelic production facilities. Read more

🌈 Main Feature

10 Million Americans microdosed in 2025… and the report says more than the headline

The headline is already making the rounds: 10 million Americans microdosed in 2025.

Easy to treat it like a “wow” stat and move on.

That misses the point.

Because the report doesn’t just measure a trend. It shows how people are using these substances, which ones are showing up most, and how normalized microdosing has become inside psychedelic use itself.

Here’s what it found in plain English:

The estimate comes out to about 3.7% of U.S. adults microdosing psilocybin, LSD, and/or MDMA in 2025 — roughly 9.55 million people, which is why the coverage rounds it to “10 million.”

Microdosing here is framed as a small dose intended to improve mood and well-being without a full psychedelic experience. That matters, because it separates “daily-life tuning” from full-dose use.

One of the most revealing parts: among people who used these substances at all, microdosing showed up as a majority behavior.

• 69% of psilocybin users reported microdosing at least once

• 65% of MDMA users reported microdosing at least once

• 59% of LSD users reported microdosing at least once

That’s the shift hiding inside the headline: for a lot of people, psychedelics aren’t being approached like a rare, high-dose “journey.” They’re being approached like a tool people reach for in smaller amounts.

The survey’s top five by estimated number of adult users:

1. Psilocybin (~11 million)

2. MDMA (~4.7 million)

3. Amanita muscaria (~3.5 million)

4. Ketamine (~3.3 million)

5. LSD (~3 million)

Even the researchers flagged how high Amanita landed — a sign that the public’s “psychedelic” category is broader and messier than the clinical or policy categories.

This wasn’t a niche poll. It was a national sample of 10,122 U.S. adults, fielded in September–October 2025, with a stated ±1.33% margin of error.

This report basically confirms what’s been true on the ground for a while:

Microdosing has become the dominant “interface” between everyday Americans and psychedelics.

Millions already normalized it quietly — while institutions still debate it like it’s theoretical.

👉 Read more

🎁 Psychedelic Utility Belt

The Psybrary is officially live!

We officially launched The Psybrary because finding reliable psychedelic information online has become harder than it should be.

Educational posts get flagged. Research links disappear. Entire accounts vanish overnight. Algorithms quietly decide what people are “allowed” to see—often without context, explanation, or appeal.

So instead of fighting every takedown one post at a time, we built something more durable.

The Psybrary is a searchable, growing knowledge hub designed to live outside the scroll and beyond algorithmic whiplash. A place where research, culture, and long-form thinking can exist without being throttled or buried.

Inside, you’ll find:

• Curated articles and deep dives

• Research breakdowns written for real humans

• Cultural stories that rarely survive platform filters

• Resources built to support informed, responsible exploration

This isn’t about chasing controversy. It’s about preserving access.

Because when information keeps disappearing, the answer isn’t always louder posts—it’s better infrastructure.

Think of the Psybrary as a utility belt you can return to when the feed stops cooperating.

👉 Explore the Psybrary

👋 Signoff

This week captured the full spectrum: hard data, shifting behavior, growing visibility, and the ongoing tension between public reality and institutional response.

Thanks for reading, and for staying thoughtful as this space continues to evolve.

We’ll keep doing the work of tracking what’s happening, preserving what disappears, and making sense of it all as honestly as we can.

Have a steady week ahead.

✅ No one can stop you from seeing what’s delivered directly to your email. 

You’re already subscribed - congratulations!

You beat the algorithm 😉 

Thank you for joining us as we continue to navigate this ever-changing landscape.

P.S. Explore what they don’t want you to see - check us out on X (Twitter) and Instagram, and dive deeper into all things psychedelic on our website. 🌐✨